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Sixty-two beagle dogs were given three doses of acet-
aminophen over a period of 24 hr in a fulminant liver 
failure model that is 70% lethal in 72 hr. Treatment of 
the animals with hepatic stimulatory substance alone 
or in a mixture with insulin, transforming growth fac-
tor-a and insulin-like growth factor II had no effect on 
mortality. Evidence of maximum regeneration with a 
mitotic index 20 to 25 times resting was the same in 
treated and untreated animals. Similarly, the biochem-
ical and hematological indexes of liver injury were un-
affected by therapy. These studies illustrate the futility 
of treating fulminant liver failure with exogenous 
growth factors that apparently are already present in 
large amounts in the natural response to liver injury. 
The results suggest that on-going liver injury by mech-
anisms other than lack of growth factors is the central 
problem of fulminant liver failure. If so, provision of re-
generation-stimulating substance is an inappropriate 
therapeutic strategy. (HEPATOLOGY 1993;17:429-433.) 
A commonly proposed strategy for treatment of fulmi-
nant liver failure (FLF) has been the administration of 
factors that can initiate and sustain hepatocyte regen-
eration (1-4). In the last several years, purified growth 
factors to confirm or refute this hypothesis have become 
available (5). We report here the testing of the hepatic 
stimulatory substance (RSS) that is found in the livers 
of weanling rats or in the regenerating liver fragments 
after partial hepatectomy (6). The RSS was infused 
alone or in combination with other hepatic stimulatory 
factors into the portal veins of dogs in which FLF was 
caused by acetaminophen in 80% of untreated animals 
(7,8). 
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MATERIALS AND METHODS 
Chemicals. Acetaminophen and DMSO were purchased 
from Sigma Chemical Co., St. Louis, MO. Hepatocyte factors 
that have been shown to be stimulatory in our Eck's fistula 
model for screening growth factors were transforming growth 
factor-a (Peninsula Laboratories Inc., Belmont, CA); human 
regular semisyntheic insulin (E.R. Squibb and Sons Inc., 
Princeton, NJ); insulin-like growth factor II (Collaborative 
Research, Inc., Bedford, MA); and HSS, produced in our 
laboratory with previously described methods (6). The HSS 
was purified 800,000 times from the cytosol of weanling rats 
(9) and had no known relation to hepatocyte growth factor of 
Zarnegar and Michalopoulos (10) and Nakamura et al. (11). We 
used doses of the continuously infused growth factors that 
were twice those shown with earlier testing in an Eck's fistula 
model to give a maximum response (5). Murine (PCNA) 
monoclonal antibody (Signet Laboratory, Inc., Dedham, MA) 
was used to detect the protein cyclin, which appears on the 
nucleus of dividing cells. 
Animals. Sixty-two beagles (Russel B. Hutton Farms, St. 
Thomas, P A) were housed in a large animal care facility and 
maintained at a constant temperature of 20° :+: 10 C, with a 
6 AM to 6 PM light cycle. The animals were quarantined and 
allowed to acclimatize in the animal facility for a minimum of 
1 wk before being used. All dogs were given a standard dry dog 
chow and water ad libitum. Their body weights ranged from 9 
to 14 kg. 
Acetaminophen Intoxication. FLF was produced with three 
subcutaneous injections of acetaminophen in DMSO (7, 8) at 
a concentration of 600 mg/ml. The first dose (750 mg!kg) was 
at noon, the second (200 mglkg) was 9 hr later and the third 
(200 mglkg) was 24 hr after the initial injection. In the original 
validation of the methods, it was demonstrated that the 
methemaglobinemia and nephrotoxicity of the acetaminophen 
could be separated from the liver injury (7), performing 
multiple injections of drug. The death of all animals herein 
reported was caused by liver failure. 
Blood or Serum Determinations. Multiple determinations 
of the serum or blood before and at various time intervals after 
acetaminophen administration were obtained. These determi-
nations included levels of serum ALT, ammonia, albumin, 
bilirubin and cholesterol and the level of blood urea nitrogen. 
Amino acid profiles were determined with plasma depro-
teinized with 4% sulfosalicyclic acid. The resultant super-
natant was applied to an amino acid analyzer (Beckman 
Instruments, Somerset, NJ), and the levels of free branched 
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FIG. 1. Survival rates of groups 1, 2 and 3 expressed in percentages. 
TABLE 1. Experimental groups and solutions infused 
No. of 
Group animals 
1 20 
2 20 
3 20 
Treatment 
Vehiclea 
HSS 100 ng/kg/day 
HSS 100 ng/kg/day, insulin 0.4 U/kg/day, 
insulin-like growth factor II 100 nglkg/day, 
transforming growth factor-a 100 ng/kg/day 
aSaline modified by the addition of ammonium acetate 5 mmol/L 
and BSA 5 mg/L. 
chain and aromatic amino acids (including tryptophan) were 
determined. 
Three coagulation parameters were measured: fibrinogen, 
factor VII and factor X (12-15). In addition, the hematocrit and 
hemoglobinuria and methemoglobinemia (16) were measured 
at each time point. 
Histological Conditions. All nonsurviving dogs underwent 
necropsies that included a full gross anatomic and microscopic 
examination of the liver, kidneys, lungs and heart. Tissues 
were fixed overnight in 10% neutral-buffered formalin, dehy-
drated, embedded in paraffin and cut into 5-fLm sections. All 
sections were stained with hematoxylin and eosin for histo-
logical examination. Other specimens were used for hepatocyte 
proliferation study. 
Hepatocyte Proliferation Measures. We determined an 
index of liver cell proliferation in a nonnecrotic area by 
counting the number of eyclin-Iabeled cells. PCNNcyclin is a 
36-kD nuclear protein that increases from the late G1 phase 
through the S phase of the cell cycle. The monoclonal antibody 
against PCNNcyclin was used with the immunoperoxidase 
method. The positive-stained cells were counted per 1,000 cells 
(17-18). 
Study Design. At laporatomy with dogs anesthetized with 
intravenous sodium pentobarbital, halothane and nitrous 
oxide, we inserted the tip of a 20-gauge catheter from ajejunal 
vein into the portal vein proximal to its bifurcation into right 
and left branches. The catheter was externalized by tunneling 
it through the body wall, and it was connected to a pump that 
delivered 20 ml saline every 24 hr. Five days later, the dogs 
were poisoned with acetaminophen by use of the protocol 
described above. Twenty hours after the acetaminophen 
injection, the animals were randomly divided into three groups 
to receive one of three different portal perfusion solutions 
(Table 1). Blood for analysis was obtained before the first 
acetaminophen injection at 24, 48 and 60 hr, subsequently. 
Liver specimens were obtained at necropsy, which was per-
formed immediately after death or after euthanasia of animals 
that appeared to be dying. 
Statistical Analysis. Survival curves were generated for the 
three groups with the Kaplan-Meier method. Median survival 
times were compared with the generalized Wilcoxon (Breslow) 
test. 
RESULTS 
Clinical Behavior. No animal died in the first 24 hr 
after acetaminophen administration. Two dogs that died 
immediately thereafter, without an increase in their 
serum level of transaminase but with very high levels of 
methemoglobinemia, were eliminated from the analysis. 
From 48 through 72 hr a progressive increase in 
mortality was observed in group 1 control animals, 
reaching 75% at 72 hr. These results were similar to 
those reported previously in untreated animals (7, 8). 
The survival rate in animals treated with HSS alone 
(group 2) or HSS plus a cocktail of other growth factors 
(group 3) was not significantly different from that in the 
group 1 controls (Fig. 1) (p = 0.934). 
All of the animals demonstrated a clinical picture 
consistent with FLF that paralleled the biochemical and 
histological data. Two different stages of the clinical 
course of these animals could be identified. The first 
stage was characterized by gastrointestinal signs and 
symptoms such as anorexia, vomiting and diarrhea. The 
second stage was characterized by the appearance 
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TABLE 2. Biochemical features in nonsurviving dogs in groups 1, 2 and 3 
Groups Ohr 24 hr 48 hr 60hr 
1 
ALT (D/L) 48 ± 5 105 ± 10 9,206 ± 3,100 24,218 ± 3,783 
Bilirubin (mg/100 m!) 1.2 ± 0.1 0.9 ± 0.2 1.8 ± 0.3 2.6 ± 0.8 
Albumin (gm/100 m!) 3.2 ± 0.4 2.6 ± 0.3 1.9 ± 0.1 1.8 ± 0.22 
Ammonia ([1mol/L) 92 ± 15 310 ± 120 304 ± 60 625 ± 250 
BCANAAA ([1mol/L) 3.14 0.88 
2 
ALT (U/L) 45 ± 4 65 ± 6 8,140 ± 9,810 21,112 ± 6,250 
Bilirubin (mg/100 ml) 1.0 ± 0.1 0.8 ± 0.7 1.2 ± 0.12 2.0 ± 0.3 
Albumin (gm/100 ml) 3.0 ± 0.35 2.5 ± 0.3 2.0 ± 0.4 1.8 ± 0.18 
Ammonia ([1mol/L) 86 ± 26 197 ± 2.8 270 ± 34 498 ± 121 
BCANAAA ([1mol/L) 3.0 ± 0.45 0.94 ± 0.04 
3 
ALT (U/L) 50 ± 5 78 ± 7 8,115 ± 3,325 20,083 ± 5,352 
Bilirubin (mg/100 ml) 0.9 ± 0.2 1.0 ± 0.2 1.1 ± 0.1 2.2 ± 0.25 
Albumin (gm/100 mll 3.2 ± 0.5 2.8 ± 0.35 2.1 ± 0.35 1.9 ± 0.19 
Ammonia ([1mol/L) 79 ± 23 186 ± 38 254 ± 62 465 ± 145 
BCANAAA ([1mol/L) 2.9 ± 0.2 0.96 ± 0.07 
BCAA = branched chain amino acid; AAA = aromatic amino acid. 
TABLE 3. Coagulation profile in nonsurviving dogs of groups 1, 2 and 3 
Groups Ohr 
1 
Fibrinogen mg/100 m! 294 ± 42 
Factor VII U/m! 50.68 ± 0.9 
Factor X U/m! 3.99 ± 0.3 
2 
Fibrinogen mg/100 m! 300 ± 54 
Factor VII Dim! 4.55 ± 0.9 
Factor X U/m! 2.99 ± 0.8 
3 
Fibrinogen mg/100 ml 320 ± 62 
Factor VII U/ml 4.00 ± 0.7 
Factor X U/ml 3.81 ± 0.2 
of neurological symptoms that rapidly progressed to 
coma. 
Biochemical and Hematological Changes. The evo-
lution of biochemical (Table 2) and hematological ab-
normalities (Table 3) was similar in the control and 
treated animals of groups 2 and 3. 
Histological Examination and Hepatocyte Prolifer-
ation. Histological examination oflivers obtained at the 
time of autopsy in dogs in groups 1, 2 and 3 demon-
strated the same severe necrosis involving all of the lobes 
that we previously reported (7). 
The number of cyclin-stained hepatocytes per 1,000 
hepatocytes was 38 to 44 in all three groups, with no 
significant difference. This finding was 20 to 25 times 
higher than the number of hepatocytes in normal dog 
livers (1.5/1,000) (Fig. 2), which was approximately 
the same as the peak response in dogs after 70% 
hepatectomy (19) and three times greater than the 
maximal response to stimulation of the Eck's fistula 
livers (5). 
24 hr 48 hr 60 hr 
140 ± 32 45 ± 18 20 ± 3 
0.80 ± 0.06 0.39 ± 0.02 0.20 ± 0.03 
0.74 ± 0.08 0.20 ± 0.02 0.19 ± 0.01 
155 ± 28 60 ± 10 37 ± 6 
0.89 ± 0.08 0.40 ± 0.06 0.20 ± 0.03 
0.90 ± 0.07 0.30 ± 0.04 0.21 ± 0.04 
188 ± 30 60 ± 11 29 ± 8 
0.90 ± 0.08 0.30 ± 0.04 0.28 ± 0.05 
0.96 ± 0.07 0.20 ± 0.03 0.25 ± 0.04 
DISCUSSION 
It has been estimated that recovery from FLF can be 
expected with 12% to 15% of the normal liver mass. The 
use of putative hepatic growth factors to achieve this 
critical functional level has been discouraging. After the 
demonstration that insulin is critical to a full expression 
of regeneration (20-23), this hormone alone (or usually 
with glucagon) has been tested for the treatment of FLF 
in mice (24), rats (25, 26) and human beings (27, 28). 
The animal studies, particularly in mice, have been 
encouraging, but the human trials have not shown a 
benefit from such treatment. The efficacy of noninsulin 
growth factors also has been controversial (29-30). 
Although the number of putative growth factors has 
greatly increased in the last decade (5, 31, 32), evalu-
ation of their therapeutic effectiveness for FLF has been 
limited by the excessive cost oftesting them and the lack 
of discriminating models that are severe enough to 
preclude spontaneous recovery but not so severe that the 
liver injury produced cannot be reversed by any means. 
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FIG. 2. Number of dividing cells determined by immunocytochemical staining of PCNNcyclin in the liver of the three groups of dogs and in 
the liver of normal dogs. 
The results described in this report could be an 
example of this quandary. In these experiments four of 
the most powerful known in vivo stimulators of hepa-
tocyte proliferation were given in a mixture after liver 
injury by acetaminophen: HSS, transforming growth 
factor-a, insulin and insulin-like growth factor II. The 
rate ofliver cell regeneration with this mixture, or when 
HSS was given as a single agent, was no greater than in 
the untreated animals; therefore the residual surviving 
cells were already maximally proliferating. Further-
more, the biochemical and hematological manifestations 
of liver injury were not ameliorated in either of the 
treatment groups nor was the mortality decreased. 
The inability to demonstrate therapeutic efficacy of 
the growth factors could mean that their use is incor-
rectly conceived and therefore futile. A high rate of 
mitosis similar to that in our animals (33, 34) has been 
reported in human beings with FLF. Evidence in 
animals subjected to carbon tetrachloride injury (35) 
and in human beings with acute hepatitis (36-37) 
suggests that at least one growth promoter, hepatic 
growth factor, increases so much that it is difficult to 
imagine a benefit from exogenous supplementation of 
this and presumably other substances that modulate 
regeneration. Alternatively, our failure to see a thera-
peutic effect with a growth factor cocktail could mean 
that the proportions of the constituents were inappro-
priate. 
However, it has been suggested recently that in FLF 
the inability of the liver to recover from injury may be a 
result of microcirculatory failure and consequential 
perpetuation of parenchymal injury, rather than a result 
of the inability of the hepatocytes to regenerate. This 
pathogenesis has been particularly evident in the 
ischemic injury of livers during preservation for use in 
transplantation (38). The primary cause of failure of 
these organs is damage to the sinusoidal endothelium 
that leads to capillary leak, complex coagulopathies and 
secondary damage to the hepatocytes by hypoperfusion 
(39). Protection of the microcirculation with prosta-
glandins (40) or measures that prevent diffuse intravas-
cular coagulation (41) may be more appropriate than the 
provision of growth factors that already are present in 
excess. 
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